Home Pain pharmacogenetics
Article
Licensed
Unlicensed Requires Authentication

Pain pharmacogenetics

  • Mariia A. Slepukhina , Dmitriy V. Ivashchenko ORCID logo , Maria A. Sheina , Andranik Alexandrovich Muradian ORCID logo EMAIL logo , Dmitriy Alexeevich Blagovestnov ORCID logo and Dmitriy A. Sychev ORCID logo
Published/Copyright: August 10, 2020
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Drug Metabolism and Personalized Therapy
From the journal Drug Metabolism and Personalized Therapy Volume 35 Issue 3

Abstract

Pain is a significant problem in medicine. The use of PGx markers to personalize postoperative analgesia can increase its effectiveness and avoid undesirable reactions. This article describes the mechanisms of nociception and antinociception and shows the pathophysiological mechanisms of pain in the human body. The main subject of this article is pharmacogenetic approach to the selection of anesthetics. Current review presents data for local and general anesthetics, opioids, and non-steroidal anti-inflammatory drugs. None of the anesthetics currently has clinical guidelines for pharmacogenetic testing. This literature review summarizes the results of original research available, to date, and draws attention to this area.

Keywords: analgesics; anesthetics; pain; pharmacogenetics
Corresponding author: Andranik Alexandrovich Muradian, Department of Urgent and General Surgery, Russian Medical Academy of Continuous Professional Education, 2/1, Barrikadnaya St., Moscow 125993, Russia, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Ethical approval: The conducted research is not related to either human or animals use.

References

1. König, H-H, Heider, D, Lehnert, T, Riedel-Heller, SG, Angermeye, MC, Matschinger, H, et al. Health status of the advanced elderly in six European countries: results from a representative survey using EQ-5D and SF-12. Heal Qual Life Outcomes 2010;8:143. https://doi.org/10.1186/1477-7525-8-143.Search in Google Scholar

2. Breivik, H, Collett, B, Ventafridda, V, Cohen, R, Gallacher, D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287. https://doi.org/10.1016/j.ejpain.2005.06.009.Search in Google Scholar

3. Gerbershagen, K, Gerbershagen, HJ, Lutz, J, Cooper-Mahkorn, D, Wappler, F, Limmroth, F, et al. Pain prevalence and risk distribution among inpatients in a German teaching hospital. Clin J Pain 2009;25:431–7. https://doi.org/10.1097/ajp.0b013e31819ff515.Search in Google Scholar

4. Brennan, F, Carr, DB, Cousins, M. Pain management: a fundamental human right. Anesth Analg 2007;105:205–21. https://doi.org/10.1213/01.ane.0000268145.52345.55.Search in Google Scholar

5. Hall, JK, Boswell, MV. Ethics, law, and pain management as a patient right. Pain Phys 2009;12:499–506.10.36076/ppj.2009/12/499Search in Google Scholar

6. Gwyther, L, Brennan, F, Harding, R. Advancing palliative care as a human right. J Pain Symptom Manag 2009;38:767–74. https://doi.org/10.1016/j.jpainsymman.2009.03.003.Search in Google Scholar

7. The Societal Impact of Pain. European positioning statement: chronic pain fundamental for European health. International multi-stakeholder platform acknowledges chronic pain as disease in its own-European policy-makers challenged to respond; 2012. [Accessed 2012].Search in Google Scholar

8. Bonica John, J, Hoffman, JF. The management of pain with special emphasis on the use of analgesic blocks in diagnosis, prognosis, and therapy. Anesth Analg 1954;85:1953–4.Search in Google Scholar

9. Raney, EB, Thankam, FG, Dilisio, MF, Agrawal, DK. Pain and the pathogenesis of biceps tendinopathy. Am J Transl Res 2017;9:2668–83.Search in Google Scholar

10. IASP terminology. Washington, DC, USA: International Association for the Study of Pain; 2018. [updated 2017 Dec 14; cited 2018 Jul 9]. Available from: https://www.iasp-pain.org/terminology?navItemNumber=576.Search in Google Scholar

11. Vardeh, D, Mannion, RJ, Woolf, CJ. Toward a mechanism-based approach to pain diagnosis. J Pain 2016;17:50–69. https://doi.org/10.1016/j.jpain.2016.03.001.Search in Google Scholar

12. IASP. Council adopts task force recommendation for third mechanistic descriptor of pain [Internet]. Washington DC, USA: International Association for the Study of Pain; 2018. [updated 2017 Nov 14; cited 2018 Jul 9]. Available from: https://www.iasp-pain.or.Search in Google Scholar

13. Ruden, RA. A neurological basis for the observed peripheral sensory modulation of emotional responses. Traumatology 2005;11:145–58. https://doi.org/10.1177/153476560501100301.Search in Google Scholar

14. Bransfield, RC, Friedman, KJ. Differentiating psychosomatic, somatopsychic, multisystem illnesses, and medical uncertainty. Healthcare 2019;7:114. https://doi.org/10.3390/healthcare7040114.Search in Google Scholar

15. Samulowitz, A, Gremyr, I, Eriksson, E, Hensing, G. “Brave Men” and “Emotional Women: a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res Manag 2018;2018:1–14. https://doi.org/10.1155/2018/6358624.Search in Google Scholar

16. Baron, R, Binder, A. Wie neuropathisch ist die Lumboischialgie? Orthopade 2004;33:568–75. https://doi.org/10.1007/s00132-004-0645-0.Search in Google Scholar

17. Freynhagen, R, Baron, R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185–90. https://doi.org/10.1007/s11916-009-0032-y.Search in Google Scholar

18. Perrot, S. Osteoarthritis pain. Best Pr Res Clin Rheumatol 2015;29:90–7. https://doi.org/10.1016/j.berh.2015.04.017.Search in Google Scholar

19. Kehlet, H, Jensen, TS, Woolf, CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006;367:1618–25. https://doi.org/10.1016/s0140-6736(06)68700-x.Search in Google Scholar

20. Freynhagen, R, Parada, HA, Calderon-Ospina, CA, Chen, J, Rakhmawati, E, Fernández-Villacorta, F, et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin 2019;35:1011–18. https://doi.org/10.1080/03007995.2018.1552042.Search in Google Scholar

21. Smith, DM, Weitzel, KW, Cavallari, LH, Elsey, AR, Schmidt, SO. Clinical application of pharmacogenetics in pain management. Per Med 2018;15:117–26. https://doi.org/10.2217/pme-2017-0032.Search in Google Scholar

22. Franceschini, N, Frick, A, Kopp, JB. Genetic testing in clinical settings. Am J Kidney Dis 2018;72:569–81. https://doi.org/10.1053/j.ajkd.2018.02.351.Search in Google Scholar

23. Lee, KC, Ma, JD, Kuo, GM. Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc 2010;50:e1–e17. https://doi.org/10.1331/japha.2010.09124.Search in Google Scholar

24. Mooney, SD. Progress towards the integration of pharmacogenomics in practice. Hum Genet 2015;134:459–65. https://doi.org/10.1007/s00439-014-1484-7.Search in Google Scholar

25. William, E, Evans, M. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–49. https://doi.org/10.1056/nejmra020526.Search in Google Scholar

26. Kirchheiner, J, Schmidt, H, Tzvetkov, M, Keulen, J, Lötsch, J, Roots, I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257–65. https://doi.org/10.1038/sj.tpj.6500406.Search in Google Scholar

27. Mercadante, S. Opioid metabolism and clinical aspects. Eur J Pharmacol 2015;769:71–8. https://doi.org/10.1016/j.ejphar.2015.10.049.Search in Google Scholar

28. Solhaug, VM. Individual variability in clinical effect and tolerability of opioid analgesics—importance of drug interactions and pharmacogenetics. Scand J Pain 2017;17:193–200. https://doi.org/10.1016/j.sjpain.2017.09.009.Search in Google Scholar

29. Cajanus, K, Kaunisto, M, Tallgren, M, Jokela, R, Kalso, E. How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism. J Pain 2014;15:1248–56. https://doi.org/10.1016/j.jpain.2014.09.002.Search in Google Scholar

30. Hajj, A, Halepian, L, Osta, N, Chahine, G, Kattan, J, Rabbaa Khabbaz, L. OPRM1 c.118A>G polymorphism and duration of morphine treatment associated with morphine doses and quality-of-life in palliative cancer pain settings. Int J Mol Sci 2017;18:669. https://doi.org/10.3390/ijms18040669.Search in Google Scholar

31. Matic, M, Jongen, J, Elens, L, de Wildt, S, Tibboel, D, Sillevis Smitt, S, et al. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Pharmacogenomics J 2017;18:1133–42. https://doi.org/10.2217/pgs-2017-0060.Search in Google Scholar

32. Krasniqi, V, Dimovski, A, Domjanović, I, Bilić, I, Bozina, N. How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada Toksikol 2016;67:1–8. https://doi.org/10.1515/aiht-2016-67-2754.Search in Google Scholar

33. Llerena, A, Alvarez, M, Dorado, P, Gonzalez, I, Peñas-LLedo, E Perez, B, et al. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics J 2013;14:229–34. https://doi.org/10.1038/tpj.2013.28.Search in Google Scholar

34. Lazarska, K, Dekker, S, Vermeulen, N, Commandeur, J. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett 2018;284:70–8. https://doi.org/10.1016/j.toxlet.2017.11.038.Search in Google Scholar

35. Nagele, P, Zeugswetter, B, Wiener, C, Burger, H, Hüpfl, M, Mittlböck, M, et al. Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 2008;109:36–43. https://doi.org/10.1097/aln.0b013e318178820b.Search in Google Scholar

36. Aroke, E, Crawford, S, Dungan, J. Pharmacogenetics of ketamine-induced emergence phenomena. Nurs Res 2017;66:105–14. https://doi.org/10.1097/nnr.0000000000000197.Search in Google Scholar

37. Li, Y, Jackson, K, Slon, B, Hardy, J, Franco, M, William, L, et al. CYP2B6*6allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol 2015;80:276–84. https://doi.org/10.1111/bcp.12614.Search in Google Scholar

38. Yağar, S, Yavaş, Karahalil, B. The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep 2010;38:3383–9.10.1007/s11033-010-0446-ySearch in Google Scholar PubMed

39. Liu, J, Xi, H, Jiang, Y, Feng, Z, Hou, L, Li, W. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy. Acta Anaesthesiol Scand 2015;59:640–7. https://doi.org/10.1111/aas.12501.Search in Google Scholar

40. Yam, M, Loh, Y, Tan, C, Khadijah, AS, Abdul, MN, Basir, R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci 2018;8:375–417. https://doi.org/10.3390/ijms19082164.Search in Google Scholar

41. Kaczmarek-Hájek, K, Lörinczi, E, Hausmann, R, Nicke, A. Molecular and functional properties of P2X receptors—recent progress and persisting challenges. Purinergic Signal 2012;8:319–27. https://doi.org/10.1007/s11302-012-9314-7.Search in Google Scholar

42. Evans, RJ. Orthosteric and allosteric binding sites of P2X receptors. Eur Biophys J 2009;38:319–27. https://doi.org/10.1007/s00249-008-0275-2.Search in Google Scholar

43. Roberts, J, Vial, C, Digby, H, Agboh, K, Wen, H, Atterbury-Thomas, A, et al. Molecular properties of P2X receptors. Pflugers Arch 2006;452:486–500. https://doi.org/10.1007/s00424-006-0073-6.Search in Google Scholar

44. Paterson, KJ, Zambreanu, L, Bennett, DLH, McMahon, SB. Characterisation and mechanisms of bradykinin-evoked pain in man using iontophoresis. Pain 2013;154:782–92. https://doi.org/10.1016/j.pain.2013.01.003.Search in Google Scholar

45. Hamza, M, Wang, X, Adam, A, Brahim, J, Rowan, J, Carmona, G, et al. Kinin B1 receptors contributes to acute pain following minor surgery in humans. Mol Pain 2010;6:1–12. https://doi.org/10.1186/1744-8069-6-12.Search in Google Scholar

46. Huang, H, Player, MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010;53:5383–99. https://doi.org/10.1021/jm1000776.Search in Google Scholar

47. Chen, JJ, Johnson, EJ. Targeting the bradykinin B1 receptor to reduce pain. Expert Opin Ther Targets 2007;11:21–35. https://doi.org/10.1517/14728222.11.1.21.Search in Google Scholar

48. George, J, Pulickal, S, Singh, A, Gautam, M, Prasoon, P, Kumar, R, et al. Locally mediated analgesic effect of bradykinin type 2 receptor antagonist HOE 140 during acute inflammatory pain in rats. J Burn Care Res 2019;35:391–8.10.1097/BCR.0000000000000042Search in Google Scholar PubMed

49. Yam, M, Loh, Y, Tan, C, Khadijah, AS, Abdul, MN, Basir, R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci 2012;8:375–417.10.3390/ijms19082164Search in Google Scholar PubMed PubMed Central

50. Guyton, AС, Hall, JE. Somatic sensations: II. Pain, headache, and thermal sensations. In: Textbook of medical physiology. Guyton and Hall; 2006.Search in Google Scholar

51. Sacerdote, P, Levrini, L. Peripheral mechanisms of dental pain: the role of substance P. Mediators Inflamm 2012:1–6.10.1155/2012/951920Search in Google Scholar PubMed PubMed Central

52. Jensen, D, Lieu, T, Halls, M, Veldhuis, N, Imlach, W, Mai, Q, et al. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief. [Letter]. Sci Transl Med 2017;9:eaal3447. https://doi.org/10.1126/scitranslmed.aal3447.Search in Google Scholar

53. Schaible, H-G. Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther 2014;16:470. https://doi.org/10.1186/s13075-014-0470-8.Search in Google Scholar

54. Clark, AK, Old, EA, Malcangio, M. Neuropathic pain and cytokines: current perspectives. J Pain Res 2013;6:803–14. https://doi.org/10.2147/jpr.s53660.Search in Google Scholar

55. Nicol, L, Thornton, P, Hatcher, J, Glover, C, Webster, C, Burrell, M, et al. Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain. Pain 2018;159:550–9. https://doi.org/10.1097/j.pain.0000000000001130.Search in Google Scholar

56. Luo, X, Wang, X, Xia, Z, Chung, SK, Cheung, CW. CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain. Rev Neurosci 2016;27:83–92. https://doi.org/10.1515/revneuro-2015-0016.Search in Google Scholar

57. Wang, X-M, Hamza, M, Wu, T-X, Dionne, RA. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: correlation to clinical pain. Pain 2009;142:275–83. https://doi.org/10.1016/j.pain.2009.02.001.Search in Google Scholar

58. Silva, RL, Lopes, AH, Guimarães, RM CT. CXCL1/CXCR2 signaling in pathological pain: role in peripheral and central sensitization. Neurobiol Dis 2017;105:109–16. https://doi.org/10.1016/j.nbd.2017.06.001.Search in Google Scholar

59. Mizumura, K, Murase, S. Role of nerve growth factor in pain. Handb Exp Pharmacol 2015;227:57–77. https://doi.org/10.1007/978-3-662-46450-2_4.Search in Google Scholar

60. Busch-Dienstfertig, M, González-Rodríguez, S. IL-4, JAK-STAT signaling, and pain. [Letter]. JAK-STAT 2013;2:e27638. https://doi.org/10.4161/jkst.27638.Search in Google Scholar

61. Schou, WS, Ashina, S, Amin, FM, Goadsby, PJ, Ashina, M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 2017;18:34. https://doi.org/10.1186/s10194-017-0741-2.Search in Google Scholar

62. Russell, FA, King, R, Smillie, S-J, Kodji, X, Brain, SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014;94:1099–42. https://doi.org/10.1152/physrev.00034.2013.Search in Google Scholar

63. Schlereth, T, Schukraft, J, Krämer-Best, HH, Geber, C, Ackermann, T, Birklein, F. Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin. Neuropeptides 2016;59:57–62. https://doi.org/10.1016/j.npep.2016.06.001.Search in Google Scholar

64. Messina, R, Goadsby, P. CGRP—a target for acute therapy in migraine: clinical data. Cephalalgia 2018;39:420–7. https://doi.org/10.1177/0333102418768095.Search in Google Scholar

65. Edvinsson, L, Haanes, KA, Warfvinge, K, Krause, DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol 2018;14:338–50. https://doi.org/10.1038/s41582-018-0003-1.Search in Google Scholar

66. Maasumi, K, Michael, RL, Rapoport, AM. CGRP and migraine: the role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs 2018;78:913–28. https://doi.org/10.1007/s40265-018-0923-5.Search in Google Scholar

67. Pellesi, L, Guerzoni, S, Pini, LA. Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol drug Dev 2017;6:534–47. https://doi.org/10.1002/cpdd.345.Search in Google Scholar

68. Zhuo, M. Ionotropic glutamate receptors contribute to pain transmission and chronic pain. Neuropharmacology 2017;112:228–34. https://doi.org/10.1016/j.neuropharm.2016.08.014.Search in Google Scholar

69. Niesters, M, Martini, C, Dahan, A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2014;77:357–67. https://doi.org/10.1111/bcp.12094.Search in Google Scholar

70. Popiolek‐Barczyk, K, Łażewska, D, Latacz, G, Olejarz, A, Makuch, W, Stark, H, et al. Antinociceptive effects of novel histamine H 3 and H 4 receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse. Br J Pharmacol 2018;175:2897–910. https://doi.org/10.1111/bph.14185.Search in Google Scholar

71. Wolińska, R, Leśniak, A, Żochowska, M, Sacharczuk, M, Kieć-Kononowicz, K, Bujalska-Zadrożny, M. Antinociceptive effect of co-administered NMDA and histamine H4 receptor antagonists in a rat model of acute pain. Pharmacol Rep 2017;69:22–228. https://doi.org/10.1016/j.pharep.2016.10.018.Search in Google Scholar

72. Ghelardini, C, Di Cesare Mannelli, L, Bianchi, E. The pharmacological basis of opioids. Clin Cases Miner Bone Metab 2015;12:219–21. https://doi.org/10.11138/ccmbm/2015.12.3.219.Search in Google Scholar

73. Toll, L, Bruchas, MR, Calo, G, Cox, BM, Zaveri, NT. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 2016;68:419–57. https://doi.org/10.1124/pr.114.009209.Search in Google Scholar

74. Butterworth, J, Mackey, D, Wasnick, J, editors. Morgan and Mikhail’s clinical anesthesiology, 6th ed. USA: McGraw-Hill Education; 2018:959–97 pp.Search in Google Scholar

75. Stein, C. Opioid receptors. Annu Rev Med 2016;67:433–51. https://doi.org/10.1146/annurev-med-062613-093100.Search in Google Scholar

76. Burston, JJ, Woodhams, SG. Endocannabinoid system and pain: an introduction. Proc Nutr Soc 2014;73:106–17. https://doi.org/10.1017/s0029665113003650.Search in Google Scholar

77. Bjorling, DE, Wang, Z-Y. Potential of endocannabinoids to control bladder pain. Front Syst Neurosci 2018;12:17. https://doi.org/10.3389/fnsys.2018.00017.Search in Google Scholar

78. Fine, PG, Rosenfeld, MJ. The endocannabinoid system, cannabinoids, and pain. [Letter]. Rambam Maimonides Med J 2013;4: e0022. https://doi.org/10.5041/rmmj.10129.Search in Google Scholar

79. Hillard, CJ. The endocannabinoid signaling system in the CNS: a primer. Int Rev Neurobiol 2015;125:1–47. https://doi.org/10.1016/bs.irn.2015.10.001.Search in Google Scholar

80. Mendiguren, A, Aostri, E, Pineda, J. Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sci 2018;192:115–27. https://doi.org/10.1016/j.lfs.2017.11.029.Search in Google Scholar

81. Davis, MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Invest Drugs 2014;23:1123–40. https://doi.org/10.1517/13543784.2014.918603.Search in Google Scholar

82. Cortes-Altamirano, J, Olmos-Hernandez, A, Jaime, H, Carrillo-Mora, P, Bandala, C, Reyes-Long, S, et al. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain response in the central nervous system. Curr Neuropharmacol 2019;16:210–21.10.2174/1570159X15666170911121027Search in Google Scholar PubMed PubMed Central

83. Ossipov, MH, Morimura, K, Porreca, F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care 2014;8:143–51.10.1097/SPC.0000000000000055Search in Google Scholar PubMed PubMed Central

84. Kirkpatrick, D, McEntire, D, Hambsch, Z, Kerfeld, M, Smith, T, Reisbig, M, et al. Therapeutic basis of clinical pain modulation. Clin Transl Sci 2015;8:848–56. https://doi.org/10.1111/cts.12282.Search in Google Scholar

85. Diniz, D, Petrocchi, J, Navarro, L, Souza, T, Castor, M, Duarte, I, et al. Serotonin induces peripheral antinociception via the opioidergic system. Biomed Pharmacother 2018;97:1434–7. https://doi.org/10.1016/j.biopha.2017.11.048.Search in Google Scholar

86. Pertovaara, A. The noradrenergic pain regulation system: a potential target for pain therapy. Eur J Pharmacol 2013;716:2–7. https://doi.org/10.1016/j.ejphar.2013.01.067.Search in Google Scholar

87. Chakraborty, S, Elvezio, V, Kaczocha, M, Rebecchi, M, Puopolo, M. Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons. J Physiol 2017;595:2639–60. https://doi.org/10.1113/jp273455.Search in Google Scholar

88. González-Ramírez, R, Chen, Y, Liedtke, WB, Morales-Lázaro, SL, editors. TRP channels and pain, 2th ed. Florida: CRC Press/Taylor & Francis; 2017:8 p.10.4324/9781315152837-8Search in Google Scholar PubMed

89. Carbone, E. Noradrenergic inhibition of presynaptic TRPV1 channels: a new pathway of pain control. J Physiol 2017;595:2413–14. https://doi.org/10.1113/jp274103.Search in Google Scholar

90. Woll, K, Zhou, X, Bhanu, N, Garcia, B, Covarrubias, M, Miller, K, et al. Identification of binding sites contributing to volatile anesthetic effects on GABA type A receptors. FASEB J 2018;32:4172–89. https://doi.org/10.1096/fj.201701347r.Search in Google Scholar

91. Lewter, L, Fisher, J, Siemian, J, Methuku, K, Poe, M, Cook, J, et al. Antinociceptive effects of a novel α2/α3-subtype selective GABAA receptor positive allosteric modulator. ACS Chem Neurosci 2017;8:1305–12. https://doi.org/10.1021/acschemneuro.6b00447.Search in Google Scholar

92. Malcangio, M. GABAB receptors and pain. Neuropharmacology 2018;136:102–5. https://doi.org/10.1016/j.neuropharm.2017.05.012.Search in Google Scholar

93. Tadavarty, R, Hwang, J, Rajput, PS, Soja, PJ, Kumar, U, Sastry, BR. Are presynaptic GABA-Cρ2 receptors involved in anti-nociception? Neurosci Lett 2015;606:145–50. https://doi.org/10.1016/j.neulet.2015.08.049.Search in Google Scholar

94. Ko, T-M, Wong, C-S, Wu, J-Y, Chen. Pharmacogenomics for personalized pain medicine. Acta Anaesthesiol Taiwanica 2016;54:24–30. https://doi.org/10.1016/j.aat.2016.02.001.Search in Google Scholar

95. Webster, L R, Belfer, I. Pharmacogenetics and personalized medicine in pain management. Clin Lab Med 2016;36:493–506. https://doi.org/10.1016/j.cll.2016.05.007.Search in Google Scholar

96. Zorina-Lichtenwalter, K, Parisien, M, Diatchenko, L. Genetic studies of human neuropathic pain conditions: a review. Pain 2018;159:583–94. https://doi.org/10.1097/j.pain.0000000000001099.Search in Google Scholar

97. Agarwal, D, Udoji, MA, Trescot, A. Genetic testing for opioid pain management: a primer. Pain Ther 2017;6:93–105. https://doi.org/10.1007/s40122-017-0069-2.Search in Google Scholar

98. Balyan, R, Mecoli, M, Venkatasubramanian, R, Chidambaran, V, Kamos, N, Clay, S, et al. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics 2017;18:337–48. https://doi.org/10.2217/pgs-2016-0183.Search in Google Scholar

99. Pratt, V, McLeod, H, Rubinstein, W, Dean, L, Kattman, B, Malheiro, A, Dean, L, editors. Medical genetics summaries [Internet]. Bethesda, MD: National Center for Biotechnology Information (US); 2012–2015:10 p.Search in Google Scholar

100. Yuan, J, Hou, J, Zhang, W, Chang, Y, Li, Z, Wang, Z, et al. CYP3A4 * 1G genetic polymorphism influences metabolism of fentanyl in human liver microsomes in Chinese patients. Pharmacology 2015;96:55–60. https://doi.org/10.1159/000433441.Search in Google Scholar

101. Takashina, Y, Naito, T, Mino, Y, Yagi, T, Ohnishi, K, Kawakami, J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet 2012;27:414–21. https://doi.org/10.2133/dmpk.dmpk-11-rg-134.Search in Google Scholar

102. Sawyer, M. A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;73:566–74. https://doi.org/10.1016/s0009-9236(03)00053-5.Search in Google Scholar

103. MacKenzie, M, Hall, R. Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. Can J Anaesth 2017;64:45–64. https://doi.org/10.1007/s12630-016-0748-1.Search in Google Scholar

104. Candiotti, K, Yang, Z, Xue, L, Zhang, Y, Rodriguez, Y, Wang, L, et al. Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. Pain Med 2013;14:1977–84. https://doi.org/10.1111/pme.12226.Search in Google Scholar

105. Zahari, Z, Lee, C, Ibrahim, M, Musa, N, Mohd Yasin, M, Lee, Y, et al. ABCB1 polymorphisms and cold pressor pain responses. Nurs Res 2017;66:134–44. https://doi.org/10.1097/nnr.0000000000000204.Search in Google Scholar

106. Chidambaran, V, Venkatasubramanian, R, Zhang, X, Martin, L, Niu, J, Mizuno, T, et al. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. Pharmacogenomics J 2016;17:162–9. https://doi.org/10.1038/tpj.2015.98.Search in Google Scholar

107. Shang, Y, Filizola, M. Opioid receptors: structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol 2015;763:206–13. https://doi.org/10.1016/j.ejphar.2015.05.012.Search in Google Scholar

108. Burford, N, Traynor, J, Alt, A. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol 2014;172:277–86. https://doi.org/10.1111/bph.12599.Search in Google Scholar

109. Chidambaran, V, Mavi, J, Esslinger, H, Pilipenko, V, Martin, L, Zhang, K, et al. Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. Pharmacogenomics J 2014;15:255–62. https://doi.org/10.1038/tpj.2014.59.Search in Google Scholar

110. Chatti, I, Woillard, JB, Mili, A, Creveaux, I, Ben Charfeddine, I, Feki, J, et al. Genetic analysis of mu and kappa opioid receptor and COMT enzyme in cancer pain Tunisian patients under opioid treatment. Iran J Public Health 2017;46:1704–11.Search in Google Scholar

111. Egan, W, Steinberg, E, Rose, J. Vitamin B12 deficiency-induced neuropathy secondary to prolonged recreational use of nitrous oxide. Am J Emerg Med 2018;36:1717e1–e2. https://doi.org/10.1016/j.ajem.2018.05.029.Search in Google Scholar

112. Miceli, F, Soldovieri, M, Ambrosino, P, De Maria, M, Manocchio, L, Medoro, A, et al. Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels. Front Cell Neurosci 2015;9:259. https://doi.org/10.3389/fncel.2015.00259.Search in Google Scholar

113. Dib-Hajj, S, Geha, P, Waxman, S. Sodium channels in pain disorders. Pain 2017;158:97–107. https://doi.org/10.1097/j.pain.0000000000000854.Search in Google Scholar

114. Reimann, F, Cox, J, Belfer, I, Diatchenko, L, Zaykin, D, McHale, D, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci 2010;107:5148–53. https://doi.org/10.1073/pnas.0913181107.Search in Google Scholar

115. Kurzawski, M, Rut, M, Dziedziejko, V, Safranow, K, Machoy-Mokrzynska, A, Drozdzik, M, et al. Common missense variant of SCN9A gene is associated with pain intensity in patients with chronic pain from disc herniation. Pain Med 2017;19:1010–14. https://doi.org/10.1093/pm/pnx261.Search in Google Scholar

116. Mansouri, M, Chafai Elalaoui, S, Ouled Amar Bencheikh, B, El Alloussi, M, Dion, P, Sefiani, A, et al. A novel nonsense mutation in SCN9A in a Moroccan child with congenital insensitivity to pain. J Pediatr Neurol 2014;51:741–4. https://doi.org/10.1016/j.pediatrneurol.2014.06.009.Search in Google Scholar

117. Marchi, M, Provitera, V, Nolano, M, Romano, M, Maccora, S, D’Amato, I, et al. A novel SCN9A splicing mutation in a compound heterozygous girl with congenital insensitivity to pain, hyposmia and hypogeusia. J Peripher Nerv Syst 2018;23:202–6. https://doi.org/10.1111/jns.12280.Search in Google Scholar

118. Duan, G, Han, C, Wang, Q, Guo, S, Zhang, Y, Ying, Y, et al. A SCN10A SNP biases human pain sensitivity. Mol Pain 2016;12:1–16. https://doi.org/10.1177/1744806916666083.Search in Google Scholar

119. Sun, J, Duan, G, Li, N, Guo, S, Zhang, Y, Ying, Y, et al. SCN11A variants may influence postoperative pain sensitivity after gynecological surgery in Chinese Han female patients. Medicine 2017;96:e8149. https://doi.org/10.1097/md.0000000000008149.Search in Google Scholar

120. Mehboob, H, Tahir, I, Iqbal, T, Saleem, S, Perveen, S, Farooqi, A. Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response 2017;15. https://doi.org/10.1177/1559325817723731.Search in Google Scholar

121. Dodiuk-Gad, R, Chung, W, Valeyrie-Allanore, L, Shear, N. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 2015;16:475–93. https://doi.org/10.1007/s40257-015-0158-0.Search in Google Scholar

122. Okamoto-Uchida, Y, Nakamura, R, Matsunaga, K, Aihara, M, Saito, Y. Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens–Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements. Pharmacogenet Genomics 2017;28:95–8. https://doi.org/10.1097/FPC.0000000000000324.Search in Google Scholar

123. Ayuso, P, Plaza-Serón, M, Doña, I, Blanca-López, N, Campo, P, Cornejo-García, J, et al. Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients. Pharmacogenet Genomics 2015;25:618–21. https://doi.org/10.1097/fpc.0000000000000179.Search in Google Scholar

Received: 2019-10-15
Accepted: 2020-03-16
Published Online: 2020-08-10

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Editorial
  2. Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative
  3. Review
  4. Pain pharmacogenetics
  5. Herbal preparations in the management of hypothyroidism in Unani medicine
  6. Mini Review
  7. Dapsone for Pneumocystis jirovecii pneumonia prophylaxis – applying theory to clinical practice with a focus on drug interactions
  8. Original Articles
  9. No effect of lipoic acid on catalytic activity of cytochrome P450 3A4
  10. Exploring the potential of pyrazoline containing molecules as Aβ aggregation inhibitors in Alzheimer’s disease
  11. Potential drug-drug interactions in ICU patients: a retrospective study
  12. Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation
  13. Silver sulfadiazine loaded breathable hydrogel sponge for wound healing
  14. Protective effect of Cyperus esculentus (tiger nut) extract against scopolamine-induced memory loss and oxidative stress in mouse brain
  15. Role of purinergic signaling pathways in the adaptogenic-like activity of methyl jasmonate in rats exposed to unpredictable chronic mild stress
https://doi.org/10.1515/dmpt-2020-2939
Keywords for this article
analgesics; anesthetics; pain; pharmacogenetics

Articles in the same Issue

  1. Editorial
  2. Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative
  3. Review
  4. Pain pharmacogenetics
  5. Herbal preparations in the management of hypothyroidism in Unani medicine
  6. Mini Review
  7. Dapsone for Pneumocystis jirovecii pneumonia prophylaxis – applying theory to clinical practice with a focus on drug interactions
  8. Original Articles
  9. No effect of lipoic acid on catalytic activity of cytochrome P450 3A4
  10. Exploring the potential of pyrazoline containing molecules as Aβ aggregation inhibitors in Alzheimer’s disease
  11. Potential drug-drug interactions in ICU patients: a retrospective study
  12. Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation
  13. Silver sulfadiazine loaded breathable hydrogel sponge for wound healing
  14. Protective effect of Cyperus esculentus (tiger nut) extract against scopolamine-induced memory loss and oxidative stress in mouse brain
  15. Role of purinergic signaling pathways in the adaptogenic-like activity of methyl jasmonate in rats exposed to unpredictable chronic mild stress
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 29.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/dmpt-2020-2939/html
Scroll to top button